Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Closure Medical's DermaBond

This article was originally published in The Gray Sheet

Executive Summary

Closure Medical's DermaBond: FDA's General and Plastic Surgery Devices panel unanimously recommends approval with conditions (8-0) of a premarket approval application for the sterile, liquid tissue adhesive for the proposed indication of topical use to "hold closed, approximated wound edges of trauma-induced lacerations or surgical incisions, including punctures from minimally invasive surgery, which otherwise could be closed with sutures of USP size 5-0 or smaller in diameter, staples, or adhesive strips." Panel members highlighted data showing that three-month cosmesis results with DermaBond were equivalent to control devices. The panel conditions its Jan. 30 recommendation on a brief addition to labeling that reminds physicians that adequate wound cleansing must be performed prior to DermaBond treatment. Panel members also recommend that labeling should state that the device is not intended to replace clinically indicated sub-dermal suture closure. Results of the company's prospective, controlled, randomized study, which involved more than 814 evaluable patients at 10 sites, showed the device to be safe and effective, the panel concluded...

You may also be interested in...



Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel